Joshua J. Meeks, MD, PhD, presented “NMIBC Trials for BCG Naive Patients: What is Exciting” at the 6th International Bladder Cancer Update on November 18, 2022, in Scottsdale, Arizona.
How to cite: Meeks, Joshua. “NMIBC Trials for BCG Naive Patients: What is Exciting.” November 2022. Accessed Nov 2024. https://grandroundsinurology.com/nmibc-trials-for-bcg-naive-patients-what-is-exciting/
NMIBC Trials for BCG Naive Patients: What is Exciting – Summary
Joshua J. Meeks, MD, PhD, Associate Professor of Urology, Biochemistry and Molecular Genetics at the Northwestern University Feinberg School of Medicine in Chicago, IL, provides insights into the latest advancements in bladder cancer research. He highlights the potential of large-scale clinical trials and the role of immunotherapy in shaping future treatment strategies. The North American trial, with a thousand patients, offers numerous opportunities to explore new treatment modalities. Additionally, the Bridge study led by Max Kate examines the efficacy of gemcitabine docetaxel compared to the standard BCG treatment. Despite initial skepticism, the trial presents promising results that may offer an alternative for patients who cannot access BCG. Dr. Meeks emphasizes the importance of identifying the patient population that would benefit most from checkpoint immunotherapy and coordinating care effectively.
He discusses ongoing trials that investigate the synergy between immunotherapy and BCG, the possibility of using less BCG, and the introduction of a Sub-Q delivery system. The Sunrise trials, TAR 200, and the Danish study DaBlaCa all hold potential in improving treatment outcomes for bladder cancer patients. Dr. Meeks concludes by highlighting the transformative impact of the Terra system, a device that delivers gemcitabine consistently and may revolutionize bladder cancer treatment. Overall, this comprehensive summary underscores the significant advancements and future prospects in bladder cancer research.
About the 6th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Dr. Meeks is an associate professor of urology, biochemistry, and molecular genetics at the Northwestern University Feinberg School of Medicine. He is a urologic surgeon with expertise in the diagnosis, treatment, and management of bladder cancer. Dr. Meeks received his MD and PhD degrees from Northwestern University in 2005, completed his urology residency at Northwestern University in 2011, and a urologic oncology fellowship at Memorial Sloan-Kettering Cancer in 2012. His research interests focus on both the molecular mechanisms involved in bladder cancer.
